Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey

Journal of the American Academy of Dermatology

Volumn 57, Issue 6, 2007, Pages 957-962

  Horn, Elizabeth J ^a   Fox, Kathleen M ^b   Patel, Vaishali ^c   Chiou, Chiun Fang ^c   Dann, Frank ^c   Lebwohl, Mark ^d  

^a National Psoriasis Foundation   (United States)

^b Strategic Healthcare Solutions LLC   (United States)

^c AMGEN INC   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PIMECROLIMUS; PSORALEN; TACROLIMUS; TAZAROTENE;

ADULT; ARTICLE; BODY SURFACE; DATA BASE; DISEASE SEVERITY; FEMALE; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; RANDOMIZATION; ULTRAVIOLET B RADIATION; VALIDATION PROCESS;

ADMINISTRATION, TOPICAL; ADULT; BIOLOGICAL THERAPY; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOTOTHERAPY; PSORIASIS;

EID: 36049003327     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.06.042     Document Type: Article

References (20)

1. Stern R.S., Nijsten T., Feldman S.R., Margolis D.J., and Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9 (2004) 136-139
2. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 14 (1996) 485-496
3. Gelfand J.M., Feldman S.R., Stern R.S., Thomas J., Rolstad T., and Margolis D.J. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 51 (2004) 704-708
4. Koo J., Lee E., Lee C.S., and Lebwohl M. Psoriasis. J Am Acad Dermatol 50 (2004) 613-622
5. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., and Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137 (2001) 280-284
6. National Psoriasis Foundation. About psoriasis: statistics. Available from: URL:http://www.psoriasis.org/about/stats. Accessed July 25, 2006.
7. de Korte J., Sprangers M.A., Mombers F.M., and Bos J.D. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 9 (2004) 140-147
8. Weiss S.C., Kimball A.B., Liewehr D.J., Blauvelt A., Turner M.L., and Emanuel E.J. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 47 (2002) 512-518
9. Rapp S.R., Feldman S.R., Exum M.L., Fleischer Jr. A.B., and Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
10. Finlay A.Y., and Coles E.C. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 132 (1995) 236-244
11. Griffiths C.E. Immunotherapy for psoriasis: from serendipity to selectivity. Lancet 359 (2002) 279-280
12. Callen J.P., Krueger G.G., Lebwohl M., McBurney E.I., Mease P., Menter A., et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 49 (2003) 897-899
13. Koo J.Y. Current consensus and update on psoriasis therapy: a perspective from the US. J Dermatol 26 (1999) 723-733
14. Ashcroft D.M., Li Wan Po A., and Griffiths C.E. Therapeutic strategies for psoriasis. J Clin Pharm Ther 25 (2000) 1-10
15. Smith C.H., Anstey A.V., Barker J.N., Burden A.D., Chalmers R.J., Chandler D., et al., British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153 (2005) 486-497
16. Feldman S.R., Fleischer Jr. A.B., and Cooper J.Z. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol 39 (2000) 41-44
17. Pearce D.J., Stealey K.H., Balkrishnan R., Fleischer Jr. A.B., and Feldman S.R. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol 45 (2006) 370-374
18. Nijsten T., Margolis D.J., Feldman S.R., Rolstad T., and Stern R.S. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 52 (2005) 434-444
19. Nijsten T., Rolstad T., Feldman S.R., and Stern R.S. Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol 141 (2005) 19-26
20. Feldman S.R., Fleischer Jr. A.B., Reboussin D.M., Rapp S.R., Exum M.L., Clark A.R., et al. The self-administered Psoriasis Area and Severity Index is valid and reliable. J Invest Dermatol 106 (1996) 183-186